Superworth

Agilent Technologies forward PE A

Share price divided by analysts' consensus earnings for the next twelve months, since 1999.

Today, Oct 23, 2026
26.4×
10-year median
25.1×
Against its 10-year history
68th
percentile: 0 is its lowest day, 100 its highest
10-year range
18.0× to 38.4×
Peer median
29.2×

Agilent Technologies' forward PE is 26.4× as of Oct 23, 2026.

That is above its ten-year median of 25.1×, higher than on 68% of days in the last ten years.

Over that time it ranged from 18.0× in Mar 2026 to 38.4× in Sep 2021.

The median for 10 diagnostics and research stocks of a similar size is 29.2×.

Forward PE over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far26.4×18.0×26.4×
202523.1×18.3×27.6×
202424.7×23.9×30.0×
202327.3×20.5×29.7×
202228.3×21.8×29.7×
202132.7×27.8×38.4×
202030.3×21.4×30.8×
201928.4×21.7×28.4×
201821.8×20.9×27.7×
201724.8×23.3×26.6×
201622.6×17.5×24.3×
201520.3×17.1×23.9×
201424.1×13.0×24.8×
201313.4×10.7×13.4×
201210.2×8.8×10.9×
20118.3×7.8×12.9×
201010.1×7.0×11.7×
200911.8×11.0×18.1×
200814.4×11.1×23.9×
200714.4×11.6×15.4×

Against its peers

Companies in Medical - Diagnostics & Research nearest Agilent Technologies' size, closest first, today.

CompanyForward PE
AAgilent Technologies26.4×
IQVIQVIA20.5×
WATWaters29.2×
IDXXIDEXX Laboratories35.9×
ILMNIllumina47.2×
MTDMettler-Toledo International33.9×
DGXQuest Diagnosticsn/m
LHLabcorp17.4×
MEDPMedpacen/m
RVTYRevvityn/m
DHRDanaher25.4×
Peer median29.2×

Where Agilent Technologies ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Agilent Technologies

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.